PATENT CLAIM ANALYSIS

Application Number: 16142831
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["424", "139100"]

Abstract:
Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Claim (Index 16):
The lyophilised formulation of claim  1 , wherein the anti-CD40 antibody comprises a heavy chain region of SEQ ID NO: 9 and a light chain region of SEQ ID NO: 10.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.61017
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15881195', '14452647', '14946170', '13991984', '13295141']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7650874069912219
- 35 USC 102 Novelty (BERT): 0.5867627242685384
- Combined Prediction Score: 0.7472549387189535
- Mean Citation Score: 354.338944
- Max Citation Score: 494.10074
- Similarity Product: 422.6459224291658

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test